Viracta Therapeutics Inc at Stifel Targeted Oncology Days (Virtual) Transcript
All right. Good afternoon, everyone. I'm Stephen Willey, one of the senior analysts here at Stifel. And glad to have with us from Viracta Therapeutics, CEO, Mark Rothera; and Chief Medical Officer, Lisa Rojkjaer.
I think Mark's going to give us a little bit of a brief overview of the company, and then I think we're going to get into some Q&A. (Conference Instructions)
But Mark and Lisa, I really appreciate you guys presenting here, and I'm going to turn it over to you.
Great. Well, firstly, Stephen, thank you very much for the invitation to the Targeted Oncology Days that Stifel's holding. It's great to be with you.
Maybe I'll just start by saying that Viracta is a targeted oncology company. It was founded in 2015 and has been a public company since 2021. And it's really all about targeting, treating, and preventing virus-associated cancers. That's our mission.
And perhaps, since this is the first
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |